The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma |
| |
| Authors: | Tomotaka Yazaki Ichiro Moriyama Hiroshi Tobita Hiroki Sonoyama Eiko Okimoto Akihiko Oka Yoshiyuki Mishima Naoki Oshima Kotaro Shibagaki Kousaku Kawashima Norihisa Ishimura Taichi Nagami Riruke Maruyama Hiroaki Shiina Shunji Ishihara |
| |
| Affiliation: | 1.Department of Internal Medicine II, Shimane University Faculty of Medicine, Japan; 2.Division of Hepatology, Shimane University Hospital, Japan; 3.Cancer Center, Shimane University Hospital, Japan; 4.Division of Endoscopy, Shimane University Hospital, Japan; 5.Inflammatory Bowel Disease Center, Shimane University Hospital, Japan; 6.Department of Urology, Shimane University Faculty of Medicine, Japan; 7.Organ Pathology Unit, Department of Pathology, Shimane University Faculty of Medicine, Japan |
| |
| Abstract: | ![]()
Immune checkpoint inhibitors (ICIs), which have anti-tumor effects, are currently approved for treatment of several kinds of advanced malignancies. However, with their increasing use, a variety of immune-related adverse events (irAEs) in administered patients have been reported. We herein report a rare case of the simultaneous onset of acute pancreatitis and colitis as irAEs during nivolumab treatment given to a patient with renal cell carcinoma, who then shown marked improvement with corticosteroid therapy. |
| |
| Keywords: | immune checkpoint inhibitor immune-related adverse event pancreatitis colitis |
|
|
